Riboflavin (Vitamin B2) and blood pressure

What 3 graded rows on riboflavin (vitamin b2) agree on for blood pressure, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Riboflavin (Vitamin B2) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Riboflavin (Vitamin B2) page, with its PubMed record.

Supplement

Riboflavin (Vitamin B2) Choose another

3 rows · 442 people

Mostly an improvement: 2 of 3 rows, and most of the people. 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a meta-analysis of 320 people (2025) and reported mixed results.

The rows run from 31 to 320 people, published from 2012 to 2025: 1 pooled review and 2 single studies.

2 improved · 1 mixed

Grade CBlood pressure in medicated hypertension with the MTHFR 677TT genotype · Improved
RCT · n 91 · 2013 · Adults with hypertension and the MTHFR 677TT genotype, without overt cardiovascular disease
1.6 mg/day · 16 weeks
Systolic blood pressure fell 5.6 mm Hg more than with placebo (141.8 to 137.1 vs 143.5 to 144.3 mm Hg); diastolic pressure did not differ.
Row on the Riboflavin (Vitamin B2) page · PubMed 23608654 (opens PubMed)
Grade CBlood pressure in cardiovascular patients with the MTHFR 677TT genotype · Improved
Crossover RCT · n 31 · 2012 · Patients with premature cardiovascular disease and the TT genotype, 4-year follow-up
1.6 mg/day · 16 weeks
Riboflavin lowered systolic blood pressure by 9.2 mm Hg and diastolic by 6.0 mm Hg overall.
Row on the Riboflavin (Vitamin B2) page · PubMed 22277556 (opens PubMed)
Grade CBlood pressure (Cochrane review) · Mixed
Meta-analysis, 4 studies · n 320 · 2025 · Adults in 4 randomized controlled trials (374 participants contributed; 320 in the systolic analysis)
Not stated in the abstract · Not stated in the abstract
Systolic pressure −1.94 mmHg (not significant; 3 studies, 320 people) and diastolic −3.03 mmHg (2 studies, 271 people), both very low-certainty evidence; riboflavin may make little to no difference to adverse events (low certainty).
Row on the Riboflavin (Vitamin B2) page · PubMed 41123035 (opens PubMed)